Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01154426 · ClinicalTrials.gov registry record · Phase 1
ABT-888 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT01154426: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT01154426 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 31 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01154426, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects and best dose of giving ABT-888 together with gemcitabine hydrochloride in treating patients with advanced solid tumors. ABT-888 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving ABT-888 together with gemcitabine hydrochloride may kill more tumor cells.
Interventions
- DRUG Gemcitabine Hydrochloride
- OTHER Diagnostic Laboratory Biomarker Analysis
- OTHER Pharmacological Study
- DRUG Veliparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2010-05 |
| Est. Completion | 2013-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01154426
The ClinicalTrials.gov registry entry for NCT01154426 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Gemcitabine Hydrochloride is the first listed.
NCT01154426 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01154426 about?
NCT01154426 is a clinical study titled "ABT-888 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors". This phase I trial is studying the side effects and best dose of giving ABT-888 together with gemcitabine hydrochloride in treating patients with advanced solid tumors. ABT-888 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such...
What is the current status of trial NCT01154426?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2010-05. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01154426?
The interventions under investigation include: Gemcitabine Hydrochloride (DRUG), Diagnostic Laboratory Biomarker Analysis (OTHER), Pharmacological Study (OTHER), Veliparib (DRUG).
Who is sponsoring clinical trial NCT01154426?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.